Literature DB >> 9886252

GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice.

R Kumar1, J Yoneda, I J Fidler, Z Dong.   

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-transduced B16-F10 murine melanoma cells had lower tumorigenicity in both syngeneic and nude mice than parental or LacZ-transduced (control) cells. The subcutaneous (s.c.) tumors producing GM-CSF were densely infiltrated with macrophages, whereas the control tumors were not. In vitro studies showed that GM-CSF-transduced B16 cells were susceptible to lysis mediated by nonactivated murine macrophages, whereas control B16 cells were not. Macrophage-mediated cytotoxicity against GM-CSF-transduced B16 cells was independent of the presence of NO, H2O2, O2-, tumor necrosis factor alpha, and matrix metalloproteinase. Coculture experiments using GM-CSF-producing and -nonproducing B16 cells demonstrated that GM-CSF produced by the transduced B16 cells activated macrophages to kill the bystander non-GM-CSF-producing tumor cells. The results suggest that GM-CSF released by tumor cells can induce macrophage-mediated cytotoxicity, which in turn can inhibit the in vivo growth of GM-CSF-transduced tumor cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886252     DOI: 10.1002/jlb.65.1.102

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  Behaviour of four different B16 murine melanoma cell sublines: C57BL/6J skin.

Authors:  Corina Danciu; Camelia Oprean; Dorina E Coricovac; Cioca Andreea; Anca Cimpean; Heinfried Radeke; Codruta Soica; Cristina Dehelean
Journal:  Int J Exp Pathol       Date:  2015-02-09       Impact factor: 1.925

2.  Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.

Authors:  Carola A S Arndt; Nadya V Koshkina; Carrie Y Inwards; Douglas S Hawkins; Mark D Krailo; Doojduen Villaluna; Peter M Anderson; Allen M Goorin; Martin L Blakely; Mark Bernstein; Sharon A Bell; Kaylee Ray; Darryl C Grendahl; Neyssa Marina; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2010-06-24       Impact factor: 12.531

3.  Murine myeloid derived suppressor cells possess a range of suppressive mechanisms-Granzyme B is not among them.

Authors:  Ellis Tibbs; Xuefang Cao
Journal:  Cancer Immunol Immunother       Date:  2022-02-07       Impact factor: 6.630

4.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

5.  Adiponectin deficiency promotes tumor growth in mice by reducing macrophage infiltration.

Authors:  Yutong Sun; Harvey F Lodish
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

Review 6.  Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.

Authors:  Rocio K Rivera-Valentin; Limin Zhu; Dennis P M Hughes
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

7.  Inhibition of UBA6 by inosine augments tumour immunogenicity and responses.

Authors:  Lei Zhang; Li Jiang; Liang Yu; Qin Li; Xiangjun Tian; Jingquan He; Ling Zeng; Yuqin Yang; Chaoran Wang; Yuhan Wei; Xiaoyue Jiang; Jing Li; Xiaolu Ge; Qisheng Gu; Jikun Li; Di Wu; Anthony J Sadler; Di Yu; Dakang Xu; Yue Gao; Xiangliang Yuan; Baokun He
Journal:  Nat Commun       Date:  2022-09-15       Impact factor: 17.694

8.  A characterization of four B16 murine melanoma cell sublines molecular fingerprint and proliferation behavior.

Authors:  Corina Danciu; Alexandra Falamas; Cristina Dehelean; Codruta Soica; Heinfried Radeke; Lucian Barbu-Tudoran; Florina Bojin; Simona Cîntă Pînzaru; Melania F Munteanu
Journal:  Cancer Cell Int       Date:  2013-07-26       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.